Full-Time

Head of Communications

Executive Director

Posted on 8/8/2024

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Compensation Overview

$260k - $301k/yr

Senior, Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Lab & Research
Life Sciences
Required Skills
Communications
Social Media
Requirements
  • 12 years of Communications experience with 5 years minimum in a biotech/pharmaceutical company or at a PR/communications agency working with biotech/pharmaceutical clients.
  • Demonstrated experience crafting and executing successful traditional media, social media and internal communications strategies.
  • Experience working with high performing teams and demonstrated ability to collaborate, lead, facilitate, influence and organize across groups and at multiple levels of an organization.
  • Understanding of SEC and FDA regulations impacting communications.
  • Education: bachelor's degree required.
Responsibilities
  • Advance RevMed's corporate visibility and drive understanding of the company's strategy, programs, capabilities and people across priority audiences, internally and externally.
  • Advance capability for external affairs, including media relations, C-suite thought leadership and executive visibility, data/regulatory milestone communications, launch readiness activities, educational campaigns and other public relations engagement tactics/channels.
  • Serve as a company spokesperson with media; develop and build relationships with top-tier business/financial/industry trade press.
  • Oversee development of communications materials, across corporate, pipeline and product communications, including launch readiness materials; materials may include press releases, talking points/Q&A, social/digital content, etc, in collaboration with external agency partners, senior leadership and internal colleagues in Investor Relations, Commercial, Medical Affairs, Patient Advocacy, Legal, and other parts of the organization.
  • In partnership with Investor Relations, plan and prepare for business and scientific events and conferences working closely across various disciplines.
  • Oversee corporate governance (e.g., annual report) and quarterly financial communications, business development communications and CSR/ESG efforts.
  • Prepare company spokespeople for media interviews and other engagements, including training spokespeople, as needed, and ensuring company spokespeople are prepared to address key issues as they emerge.
  • Develop and oversee comprehensive, and compliant corporate branding strategy.
  • Build and execute well organized and consistent internal communications capabilities to support employee engagement, understanding, alignment and inclusion.
  • Collaborate with HR to ensure employee communications are well coordinated and aligned to broader internal and external objectives and messaging.
  • Demonstrate an unwavering commitment to patients, in alignment with patient advocacy function, and oversee efforts on patient-focused communication/engagement programs to drive employee engagement and promote the voice of the patient.
  • Oversee and provide counsel for issues/crisis communications.
  • Oversee social/digital and omnichannel strategy internally and externally.
  • Manage future direct reports and multiple agency partners.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to tailor their research and development efforts to this specific area. Their goal is to improve cancer treatment outcomes for patients with RAS mutations by providing effective targeted therapies.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

7%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.

INACTIVE